Virax Biolabs Group Limited (VRAX)
Develops blood tests that measure immune cell responses to detect long COVID and similar post-infection conditions
$2.88-0.07%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-86.4%
The outlook
VRAX is trading near its 52-week low, sitting well below both its 50- and 200-day moving averages, which suggests downward momentum in the near term. Analyst coverage leans bearish overall, though the average price target sits significantly above the current price. The stock remains deeply depressed within its annual range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +768% vs current price
Market cap
$2.3M
52-wk high
$25.00
52-wk low
$2.50
50-day avg
$4.41
200-day avg
$7.20
Trailing P/E
—